Suppr超能文献

SMRT共抑制因子与早幼粒细胞白血病相关的PLZF、早幼粒细胞白血病锌指蛋白-视黄酸受体α(RARα)及PLZF-RARα癌蛋白相互作用。

SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.

作者信息

Hong S H, David G, Wong C W, Dejean A, Privalsky M L

机构信息

Section of Microbiology, Division of Biological Sciences, University of California, Davis, CA 95616, USA.

出版信息

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9028-33. doi: 10.1073/pnas.94.17.9028.

Abstract

Retinoic acid receptors (RARs) are hormone-regulated transcription factors that control key aspects of normal differentiation. Aberrant RAR activity may be a causal factor in neoplasia. Human acute promyelocytic leukemia, for example, is tightly linked to chromosomal translocations that fuse novel amino acid sequences (denoted PML, PLZF, and NPM) to the DNA-binding and hormone-binding domains of RARalpha. The resulting chimeric receptors have unique transcriptional properties that may contribute to leukemogenesis. Normal RARs repress gene transcription by associating with ancillary factors denoted corepressors (also referred to as SMRT, N-CoR, TRAC, or RIP13). We report here that the PML-RARalpha and PLZF-RARalpha oncoproteins retain the ability of RARalpha to associate with corepressors, and that this corepressor association correlates with certain aspects of the leukemic phenotype. Unexpectedly, the PLZF moiety itself can interact with SMRT corepressor. This interaction with corepressor is mediated, in part, by a POZ motif within PLZF. Given the presence of POZ motifs in a number of known transcriptional repressors, similar interactions with SMRT may play a role in transcriptional silencing by a variety of both receptor and nonreceptor transcription factors.

摘要

维甲酸受体(RARs)是受激素调节的转录因子,可控制正常分化的关键环节。RAR异常活性可能是肿瘤形成的一个致病因素。例如,人类急性早幼粒细胞白血病与染色体易位紧密相关,这些易位将新的氨基酸序列(分别称为PML、PLZF和NPM)融合到RARα的DNA结合域和激素结合域。由此产生的嵌合受体具有独特的转录特性,可能有助于白血病的发生。正常的RARs通过与称为共抑制因子(也称为SMRT、N-CoR、TRAC或RIP13)的辅助因子结合来抑制基因转录。我们在此报告,PML-RARα和PLZF-RARα癌蛋白保留了RARα与共抑制因子结合的能力,并且这种共抑制因子结合与白血病表型的某些方面相关。出乎意料的是,PLZF部分本身可以与SMRT共抑制因子相互作用。这种与共抑制因子的相互作用部分是由PLZF内的一个POZ基序介导的。鉴于许多已知的转录抑制因子中都存在POZ基序,与SMRT的类似相互作用可能在多种受体和非受体转录因子的转录沉默中发挥作用。

相似文献

引用本文的文献

8
Therapeutic Potential of Targeting the SUMO Pathway in Cancer.靶向SUMO通路在癌症治疗中的潜力
Cancers (Basel). 2021 Aug 31;13(17):4402. doi: 10.3390/cancers13174402.

本文引用的文献

2
Transcriptional control. Sinful repression.转录控制。罪恶的抑制。
Nature. 1997 May 1;387(6628):16-7. doi: 10.1038/387016a0.
5
Nuclear receptor coactivators and corepressors.核受体共激活因子与共抑制因子。
Mol Endocrinol. 1996 Oct;10(10):1167-77. doi: 10.1210/mend.10.10.9121485.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验